A Disease-specific IPS Cell Resource for Studying Rare and Intractable Diseases

Overview

Journal Inflamm Regen

Publisher Biomed Central

Date 2023 Sep 8

PMID 37684663

Authors

Megumu K Saito

Mitsujiro Osawa

Nao Tsuchida

Kotaro Shiraishi

Akira Niwa

Knut Woltjen

Isao Asaka

Katsuhisa Ogata

Suminobu Ito

Shuzo Kobayashi

Shinya Yamanaka

Affiliations

Soon will be listed here.

Abstract

Background: Disease-specific induced pluripotent stem cells (iPSCs) are useful tools for pathological analysis and diagnosis of rare diseases. Given the limited available resources, banking such disease-derived iPSCs and promoting their widespread use would be a promising approach for untangling the mysteries of rare diseases. Herein, we comprehensively established iPSCs from patients with designated intractable diseases in Japan and evaluated their properties to enrich rare disease iPSC resources.

Methods: Patients with designated intractable diseases were recruited for the study and blood samples were collected after written informed consent was obtained from the patients or their guardians. From the obtained samples, iPSCs were established using the episomal method. The established iPSCs were deposited in a cell bank.

Results: We established 1,532 iPSC clones from 259 patients with 139 designated intractable diseases. The efficiency of iPSC establishment did not vary based on age and sex. Most iPSC clones originated from non-T and non-B hematopoietic cells. All iPSC clones expressed key transcription factors, OCT3/4 (range 0.27-1.51; mean 0.79) and NANOG (range 0.15-3.03; mean 1.00), relative to the reference 201B7 iPSC clone.

Conclusions: These newly established iPSCs are readily available to the researchers and can prove to be a useful resource for research on rare intractable diseases.

Citing Articles

Correction of Griscelli Syndrome Type 2 causing mutations in the gene with CRISPR/Cas9.

Erol O, Senocak S, Ozcimen B, Guney Esken G, Kilic H, Kocaefe C Turk J Biol. 2024; 48(5):290-298.

PMID: 39474038 PMC: 11518329. DOI: 10.55730/1300-0152.2705.

Clinical trials in-a-dish for cardiovascular medicine.

Wu X, Swanson K, Yildirim Z, Liu W, Liao R, Wu J Eur Heart J. 2024; 45(40):4275-4290.

PMID: 39270727 PMC: 11491156. DOI: 10.1093/eurheartj/ehae519.

Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells.

Nakamura Y, Niho S, Shimizu Y Cells. 2024; 13(11.

PMID: 38891026 PMC: 11172081. DOI: 10.3390/cells13110893.

References

Anderson R, Francis K . Modeling rare diseases with induced pluripotent stem cell technology. Mol Cell Probes. 2018; 40:52-59. PMC: 6033695. DOI: 10.1016/j.mcp.2018.01.001. View

Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T . Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013; 499(7459):481-4. DOI: 10.1038/nature12271. View

Boycott K, Lau L, Cutillo C, Austin C . International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol Med. 2019; 11(5). PMC: 6505568. DOI: 10.15252/emmm.201910486. View

Takasato M, Er P, Chiu H, Maier B, Baillie G, Ferguson C . Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 2015; 526(7574):564-8. DOI: 10.1038/nature15695. View

Lancaster M, Renner M, Martin C, Wenzel D, Bicknell L, Hurles M . Cerebral organoids model human brain development and microcephaly. Nature. 2013; 501(7467):373-9. PMC: 3817409. DOI: 10.1038/nature12517. View

Marwaha S, Knowles J, Ashley E . A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022; 14(1):23. PMC: 8883622. DOI: 10.1186/s13073-022-01026-w. View

Nichols J, Zevnik B, Anastassiadis K, Niwa H, Chambers I, Scholer H . Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998; 95(3):379-91. DOI: 10.1016/s0092-8674(00)81769-9. View

Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K . The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113(5):631-42. DOI: 10.1016/s0092-8674(03)00393-3. View

Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H . National Registry of Designated Intractable Diseases in Japan: Present Status and Future Prospects. Neurol Med Chir (Tokyo). 2016; 57(1):1-7. PMC: 5243159. DOI: 10.2176/nmc.st.2016-0135. View

10.

Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H . How many rare diseases are there?. Nat Rev Drug Discov. 2020; 19(2):77-78. PMC: 7771654. DOI: 10.1038/d41573-019-00180-y. View

11.

Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A . An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2012; 31(3):458-66. DOI: 10.1002/stem.1293. View

12.

Agu C, Soares F, Alderton A, Patel M, Ansari R, Patel S . Successful Generation of Human Induced Pluripotent Stem Cell Lines from Blood Samples Held at Room Temperature for up to 48 hr. Stem Cell Reports. 2015; 5(4):660-71. PMC: 4624992. DOI: 10.1016/j.stemcr.2015.08.012. View

13.

Kawasaki Y, Oda H, Ito J, Niwa A, Tanaka T, Hijikata A . Identification of a High-Frequency Somatic NLRC4 Mutation as a Cause of Autoinflammation by Pluripotent Cell-Based Phenotype Dissection. Arthritis Rheumatol. 2016; 69(2):447-459. DOI: 10.1002/art.39960. View

14.

Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T . Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2007; 26(1):101-6. DOI: 10.1038/nbt1374. View

15.

Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A . Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. Physiol Rev. 2018; 99(1):79-114. DOI: 10.1152/physrev.00039.2017. View

16.

Ronen D, Benvenisty N . Sex-dependent gene expression in human pluripotent stem cells. Cell Rep. 2014; 8(4):923-32. DOI: 10.1016/j.celrep.2014.07.013. View

17.

Milagre I, Stubbs T, King M, Spindel J, Santos F, Krueger F . Gender Differences in Global but Not Targeted Demethylation in iPSC Reprogramming. Cell Rep. 2017; 18(5):1079-1089. PMC: 5300890. DOI: 10.1016/j.celrep.2017.01.008. View

18.

Karagiannis P, Yamanaka S, Saito M . Application of induced pluripotent stem cells to primary immunodeficiency diseases. Exp Hematol. 2019; 71:43-50. DOI: 10.1016/j.exphem.2019.01.005. View

19.

Ye L, Muench M, Fusaki N, Beyer A, Wang J, Qi Z . Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors. Stem Cells Transl Med. 2013; 2(8):558-66. PMC: 3726135. DOI: 10.5966/sctm.2013-0006. View

20.

Taniguchi-Ikeda M, Koyanagi-Aoi M, Maruyama T, Takaori T, Hosoya A, Tezuka H . Restoration of the defect in radial glial fiber migration and cortical plate organization in a brain organoid model of Fukuyama muscular dystrophy. iScience. 2021; 24(10):103140. PMC: 8487058. DOI: 10.1016/j.isci.2021.103140. View